Press Releases

  • No categories
    • April 22, 2024

    Atamyo Therapeutics Announces Scientific Communications on its LGMD Programs and Participation in Conferences

    Five upcoming communications on LGMD programs at Myology 2024 Congress CEO Stephane Degove to present corporate overview at BioEquity Europe 2024 Evry, France (April 22, 2024) – Atamyo Therapeutics, a clinical-stage biotechnology company focused on […]

    Read more
    March 26, 2024

    Atamyo Therapeutics obtient les autorisations réglementaires en Europe pour lancer l’essai clinique de ATA-200, sa thérapie génique pour traiter la myopathie des ceintures LGMD-2C/R5

    Atamyo a reçu les autorisations en France et en Italie d’un essai clinique pour sa thérapie génique ATA-200 ATA-200 est une thérapie génique à injection unique visant à traiter la LGMD2C/R5 causée par des mutations […]

    Read more

    Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5

    Atamyo has received approval to initiate a clinical trial of ATA-200 gene therapy in France and Italy ATA-200 is a single-injection gene therapy aimed to treat LGMD2C/R5 caused by mutations in the gamma–sarcoglycan gene The […]

    Read more